Antigen-SpecificImmunomodulation in Multiple Sclerosis by IL-10 -TCell Receptor-Like Antibodies (TCRL) Fusion Proteins
Multiple sclerosis (MS) is anautoimmune disease of the central nervous system (CNS) leading to demyelinationand disability. MS treatments are particularly effective during the earlyphase, but have little effect during the progressive phase, which is targetedby a local innate immune response.
This study aims to construct,produce, and characterize an IL-10 TCRL Ab fusion protein directed against theMS autoantigen MOG35-55 in a context of HLA-DR2 complex conjugated with thestrong anti-inflammatory cytokine Interleukin-10 (IL-10), and test its abilityto induce site-specific immunomodulation.
